P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance.

Chronic bronchitis is in part characterized by mucus hypersecretion and the inability to clear airways of mucus. Despite years of research in this area, to date there are no pharmacologic therapies available to enhance or promote mucociliary clearance. P2Y(2) receptor agonists are a new class of mucoactive compounds that are currently under development for this purpose. This article will review the pharmacology of P2Y(2) receptor agonists, review the clinical studies performed to date, and highlight the challenges inherent in the development of therapies with these pharmacologic properties.

[1]  R. Gibson,et al.  Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: Results of a phase I multi‐center study , 2001, Pediatric pulmonology.

[2]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[3]  W. Bennett,et al.  Effect of aerosolized uridine 5'-triphosphate on mucociliary clearance in mild chronic bronchitis. , 2001, American journal of respiratory and critical care medicine.

[4]  C. W. Davis,et al.  Differential effects of UTP, ATP, and adenosine on ciliary activity of human nasal epithelial cells. , 2001, American journal of physiology. Cell physiology.

[5]  I. Sims,et al.  Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. , 2001, Bioorganic & medicinal chemistry letters.

[6]  B. Rubin,et al.  Evaluating the efficacy of mucoactive aerosol therapy. , 2000, Respiratory care.

[7]  P. Poole,et al.  Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. , 2000, The Cochrane database of systematic reviews.

[8]  R. Boucher,et al.  Biochemical evidence for an ecto alkaline phosphodiesterase I in human airways. , 2000, American journal of respiratory cell and molecular biology.

[9]  M. K. James,et al.  Aerosolization of P2Y(2)-receptor agonists enhances mucociliary clearance in sheep. , 1999, Journal of applied physiology.

[10]  B. Yerxa,et al.  P2Y2 receptors agonists: Structure, activity and therapeutic utility , 1999 .

[11]  M. King,et al.  Effect of aerosolized uridine-5'-triphosphate on airway clearance with cough in patients with primary ciliary dyskinesia. , 1999, American journal of respiratory and critical care medicine.

[12]  S. Randell,et al.  Evidence for Periciliary Liquid Layer Depletion, Not Abnormal Ion Composition, in the Pathogenesis of Cystic Fibrosis Airways Disease , 1998, Cell.

[13]  L. Allegra,et al.  Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. , 1996, Respiration; international review of thoracic diseases.

[14]  T. Akiyama,et al.  Nucleotide-induced mucin release from primary hamster tracheal surface epithelial cells involves the P2u purinoceptor. , 1996, The European respiratory journal.

[15]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[16]  Z. Lu,et al.  P2u purinoceptor stimulation of surfactant secretion coupled to phosphatidylcholine hydrolysis in type II cells. , 1994, The American journal of physiology.

[17]  T. Evald,et al.  Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. , 1994, Respiratory medicine.

[18]  J. Zahm,et al.  Effect of extracellular ATP and UTP on fluid transport by human nasal epithelial cells in culture. , 1994, American journal of respiratory cell and molecular biology.

[19]  M. Knowles,et al.  Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. , 1991, The New England journal of medicine.

[20]  R. Boucher,et al.  Regulation of transepithelial ion transport and intracellular calcium by extracellular ATP in human normal and cystic fibrosis airway epithelium , 1991, British journal of pharmacology.

[21]  T. Petty.  The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. , 1990, Chest.

[22]  J. B. Rasmussen,et al.  Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. , 1988, The European respiratory journal.

[23]  G. Guyatt,et al.  A controlled trial of ambroxol in chronic bronchitis. , 1987, Chest.

[24]  G. Boman,et al.  Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. , 1983, European journal of respiratory diseases.

[25]  Long-term oral acetylcysteine in chronic bronchitis. a double-blind controlled study. , 1980, European journal of respiratory diseases. Supplement.

[26]  G. Burnstock.  Purinergic nerves. , 1972, Pharmacological reviews.

[27]  G. Burnstock,et al.  Evidence that adenosine triphosphate or a related nucleotide is the transmitter substance released by non‐adrenergic inhibitory nerves in the gut , 1997, British journal of pharmacology.